依洛尤单抗短期快速调脂在高危急性冠状动脉综合征患者中应用价值

The application value of Evolocumab for short-term rapid lipid regulation in high-risk patients with acute coronary syndrome

目的探讨依洛尤单抗的调脂疗效、安全性以及在极高危急性冠状动脉综合征(ACS)患者中的应用价值。方法选取2019年2-7月北部战区总医院心血管内科收治的35例高脂血症合并ACS的患者为研究对象。所有患者均在他汀类药物治疗的基础上加用依洛尤单抗140 mg皮下注射(他汀类药物不耐受患者单用依洛尤单抗),7~10 d后复查血脂指标,比较用药前后血脂指标的变化情况。结果应用依洛尤单抗后,患者的总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇(LDL-C)均较用药前明显下降,差异有统计学意义(P<0.05)。其中,LDL-C较用药前降幅达59.84%,LDL-C降至1.80 mmol/L者达28例(80.00%)。结论依洛尤单抗可快速降低患者的胆固醇和LDL-C水平,对甘油三酯也有明显改善效果,有望成为降脂治疗领域一个新的里程碑式的药物。

Objective To investigate the efficacy,safety and application value of Evolocumab in patients with acute coronary syndrome(ACS).Methods A retrospective study was performed on 35 cases of patients with hyperlipidemia complicated with ACS who were admitted from February to July 2019.On the basis of statin treatment,all patients were treated with Evolocumab 140 mg and subcutaneously injected(patients with statin intolerance were treated with Evolocumab alone).After 7-10 days,the blood lipid indexes were reviewed and the changes of blood lipid indexes before and after the treatment were compared.Results Total cholesterol,triglyceride,high-density lipoprotein cholesterol and low-density lipoprotein cholesterol(LDL-C)all decreased significantly after administration of Evolocumab,and the difference was statistically significant(P<0.05).Among them,LDL-C reduced by 59.84%compared with before treatment,and LDL-C reduced to 1.80 mmol/L in 28 cases(80.00%).Conclusion Evolocumab can rapidly change patients’cholesterol and LDL-C,and has a significant improvement effect on triglycerides,which is expected to be a new milestone drug in the field of lipid-lowering therapy.